Search | Clinical Trials Finder

Conditions: Hypertension
Interventions: Nesiritide (BNP), Placebo; Drug
Lead sponsor: John C Burnett; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ebola Virus Infection
Interventions: TKM-100201, Placebo; Drug
Lead sponsor: Arbutus Biopharma Corporation; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Uremic Pruritus
Interventions: CR845 0.5 mcg/kg, Placebo; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 29
States / cities: Chula Vista, California • Fountain Valley, California • Northridge, California + 25 more

Conditions: Healthy
Interventions: JNJ-54452840, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Covid19
Interventions: Angiotensin-(1-7), Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Nonsquamous Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, Placebo matching lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 761 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 17
States / cities: Mountain View, California • New Haven, Connecticut • Fort Lauderdale, Florida + 13 more

Conditions: Urothelial Carcinoma
Interventions: Atezolizumab, Carboplatin, Gemcitabine, Placebo, Cisplatin; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 18
States / cities: Rogers, Arkansas • San Luis Obispo, California • New Haven, Connecticut + 15 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: NP001, Placebo; Drug
Lead sponsor: Neuraltus Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more

Conditions: Acute Kidney Injury
Interventions: Iopamidol 300 (Contrast), Placebo (Normal Saline); Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Complex Regional Pain Syndrome Type I
Interventions: Neridronate, Placebo; Drug
Lead sponsor: Ambros Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 27 more

Conditions: End-Stage Renal Disease, Kidney Transplantation
Interventions: Intravenous immune globulin (IVIG); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Pain, Acute
Interventions: Intravenous oxytocin, Intravenous placebo, Intranasal oxytocin, Intranasal placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: HIV Infections
Interventions: VRC07-523LS, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: Sepsis, Community Acquired Pneumonia (CAP)
Interventions: OPT101, Placebo; Drug · Other
Lead sponsor: Op-T LLC; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Multifocal Motor Neuropathy (MMN)
Interventions: ARGX-117, Placebo; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 6
States / cities: Scottsdale, Arizona • Glenview, Illinois • Minneapolis, Minnesota + 3 more

Conditions: Breast Cancer
Interventions: Enzalutamide, Placebo, Paclitaxel; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 6
States / cities: Topeka, Kansas • Metairie, Louisiana • The Bronx, New York + 3 more

Conditions: Delirium
Interventions: Ketamine (0.5 mg/kg), Normal Saline (placebo), Ketamine (1 mg/kg); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Postoperative Pain, Hysterectomy
Interventions: IV Acetaminophen, IV Placebo 100 mL solution; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 27
States / cities: Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 21 more

Conditions: Major Depression
Interventions: Psilocybin (Usona Institute), Propofol, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 25 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Postoperative Pain
Interventions: CR845, Placebo; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 18
States / cities: Florence, Alabama • Mobile, Alabama • Montgomery, Alabama + 14 more

Conditions: Metastatic Non Small Cell Lung Cancer
Interventions: Pembrolizumab/Vibostolimab coformulation, Docetaxel, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more

Conditions: Fever, Oxidative Stress
Interventions: Intravenous Acetaminophen, Oral Acetaminophen; Drug
Lead sponsor: Richmond University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Autoimmune Diseases, Mental Disorders Diagnosed in Childhood, Schizophrenia
Interventions: Intravenous immunoglobulin; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atherosclerosis
Interventions: LS followed by NS diet condition, NS followed by LS diet condition, Placebo, RO6836191; Other · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Marlton, New Jersey

Search by objective public record fields.

Nesiritide in Resistant Hypertension

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion

CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants

Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

Double-Blind Placebo-Controlled CIN Trial

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)

An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer

The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial

Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery

Study of Psilocybin Under Anesthesia Controlled by EEG

Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

Reduction of Intrapartum Fever With Intravenous Acetaminophen

Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)

A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.